ADMS News and Press, Adamas Pharmaceuticals Inc. From 07/23/20

EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conf...

Adamas Pharmaceuticals ( ADMS +4.5% )  announces new post-hoc Phase 3 data showing that Gocovri decreased dyskinesia and OFF time (periods where levodopa therapy is not working well) in people with Parkinson’s Disease (PD). More news on: Adamas Pharmaceuticals, Inc., He...

EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivo...

Xeris Pharma Reports Positive Topline Data for Insulin Trial Xeris Pharmaceuticals ( XERS ) reported positive data for its Phase 2 clinical trial for diabetes. The drug candidate XP-3924 is an o-formulation of pramlintide and insulin and the trial aimed to assess its potential in treati...

Gainers:  ELOX +52.1% . ORN +17.7% . TMBR +8.5% . ABM +8.0% . DADA +7.2% . More news on: Eloxx Pharmaceuticals, Inc., Orion Group Holdings, Inc., Timber Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Citing "limited" commercial opportunity and the need to conduct another late-stage clinical trial, Adamas Pharmaceuticals (NASDAQ: ADMS ) has decided to terminate development of ADS-5102 (amantadine) extended-release capsules for the treatment multiple sclerosis (MS) patients with walkin...

EMERYVILLE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of AD...

Heron Reports Positive Results From Mid-Stage Knee Replacement Trial Heron Therapeutics (HRTX) announced that its Phase 2b clinical trial Study 209 has provided positive data with regard to HTX-011. The trial involved testing the drug candidate on patients undergoing total knee arthropla...

The FDA accepts for review Adamas Pharmaceuticals' (NASDAQ: ADMS ) supplemental marketing application seeking approval to use Gocovri (amantadine) to treat OFF episodes in Parkinson's disease (PD) patients receiving levodopa-based therapy. The agency's action date is February 1, 2021....

EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Applica...